Entrada Therapeutics (TRDA) Expected to Announce Quarterly Earnings on Wednesday

Posted by Joseph Casey on Mar 11th, 2025

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) will likely be announcing its earnings results before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.68) per share and revenue of $12.92 million for the quarter.

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.69. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The firm had revenue of $12.25 million during the quarter, compared to analysts’ expectations of $11.95 million. On average, analysts expect Entrada Therapeutics to post $1 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Entrada Therapeutics Stock Down 2.5 %

Shares of TRDA stock opened at $10.50 on Tuesday. The business’s 50 day moving average is $13.37 and its two-hundred day moving average is $15.98. Entrada Therapeutics has a 12 month low of $10.26 and a 12 month high of $21.79. The company has a market cap of $394.75 million, a PE ratio of 6.60 and a beta of -0.14.

Analyst Upgrades and Downgrades

TRDA has been the topic of several recent analyst reports. Roth Capital upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Entrada Therapeutics in a research report on Tuesday, February 25th. Finally, Roth Mkm started coverage on Entrada Therapeutics in a research report on Thursday, December 5th. They set a “buy” rating and a $29.00 price objective for the company.

Check Out Our Latest Analysis on Entrada Therapeutics

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.